Form 4: Amgen Director Charles M. Holley Reports Acquisition of Common Stock

Director Charles M. Holley reports acquiring Amgen common stock through restricted stock units and dividend equivalents.

Summary

• Charles M. Holley, a director of Amgen Inc., filed a Form 4 to report changes in beneficial ownership.
• On May 6, 2025, Holley acquired 157.1513 shares of Amgen common stock at $0 per share.
• These shares were acquired through Restricted Stock Units (RSUs) granted under the Amgen Inc. 2009 Director Incentive Program, as amended, and vested immediately.
• The report also indicates that Holley owns 10,428.1742 shares of common stock directly and 1,260 shares indirectly through the Holley Family Trust.
• The direct holdings include 1,209 Dividend Equivalents (DEs) granted pursuant to the Director Program.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The acquisition of shares by a director is generally a good sign, but it's part of a standard compensation plan, so it's not a major event.

Positives

• The acquisition of shares by a director can be seen as a positive sign, indicating confidence in the company's future performance.
• The immediate vesting of RSUs suggests a strong incentive for the director to contribute to the company's success.

Future Outlook

The document does not contain specific forward-looking statements, but the ongoing Director Incentive Program suggests continued equity-based compensation for directors.

Industry Context

Director share ownership is a common practice in publicly traded companies to align the interests of management with those of shareholders. This filing reflects standard compensation practices within the pharmaceutical industry.

Comparison to Industry Standards

• Equity compensation for board members is a common practice among large pharmaceutical companies like Pfizer (PFE), Johnson & Johnson (JNJ), and Merck (MRK).
• These companies often use a mix of stock options, restricted stock units, and cash compensation to incentivize and retain directors.
• The specific terms of Amgen's Director Incentive Program, such as vesting schedules and dividend equivalents, are likely benchmarked against industry peers to ensure competitiveness.

Stakeholder Impact

• The acquisition of shares by a director can have a slightly positive impact on shareholder confidence.
• The Director Incentive Program aligns the interests of the director with those of the shareholders.

Key Dates

Keywords

Amgen, Director, Charles M. Holley, Form 4, Beneficial Ownership, Common Stock, Restricted Stock Units, Dividend Equivalents, Director Incentive Program